Clinical

Dataset Information

0

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer


ABSTRACT: In this study, participants with locally advanced rectal cancer patients will be treated according to MMR/MSI status. There will be two cohorts in this study: Cohort A and Cohort B. For Cohort A, dMMR or MSI-H patients will receive 4 cycles of neoadjuvant Pd1 antibody Sintilimab,followed by one of the following treatments: (1) surgery and adjuvant treatment, (2)another 4 cycles of sintilimab, followed by radical surgery or observation (only for cCR) . For Cohort B, pMMR/MSS/MSI-L patients will be randomized to receive neoadjuvant chemoradiotherapy ± four cycles of Pd1 antibody Sintilimab,followed by one of the following treatments: (1) curative surgery and four cycles of adjuvant chemotherapy;(2)four cycles of chemotherapy then observation (only cCR after neoadjuvant therapy)

DISEASE(S): Colorectal Neoplasms,Colorectal Cancer Stage Ii,Colorectal Cancer Stage Iii

PROVIDER: 2332769 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2016-03-24 | E-GEOD-43816 | biostudies-arrayexpress
2012-12-11 | GSE42822 | GEO
2024-05-17 | GSE241934 | GEO
2012-12-11 | E-GEOD-42822 | biostudies-arrayexpress
2015-05-11 | E-GEOD-68629 | biostudies-arrayexpress
2015-05-11 | GSE68629 | GEO
2024-09-24 | GSE264695 | GEO
2023-01-12 | GSE216333 | GEO
2023-05-31 | GSE233517 | GEO
2016-03-24 | GSE43816 | GEO